Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) among Substance Use Disorder (SUD) Populations: Meta-Analysis.
Open accessThe DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index; 3 of the 15 sources its claims cite were checked for support.
Abstract
(1) Background: Attention deficit hyperactivity disorder (ADHD) is characterized by a persistent pattern of age-inappropriate levels of inattention and/or hyperactivity/impulsivity that results in functional impairment at work, education, or hobbies and affects family life, social contacts, and self-confidence. ADHD is a comorbid condition associated with a prognosis of severe substance use disorder (SUD) and the early onset of such. The aim of this meta-analysis was to obtain the best estimate of the prevalence of ADHD in SUD populations. (2) Methods: A literature research was conducted using PUBMED® and Web of Science®. The following search terms were used: [ADHD], [prevalence], and [substance use disorder]. RStudio® was used for meta-analysis methods. (3) Results: In total, 31 studies were included. We estimate the prevalence of ADHD among SUD patients at 21%.
Overview
CoChat Summary
## TL;DR
This meta-analysis pooled 31 studies (12,524 participants) to estimate the prevalence of ADHD among people with substance use disorder (SUD). It found an overall ADHD prevalence of 21%, with similarly high but substance-specific estimates for cocaine (19%), opioids (18%), and alcohol (25%).
## Key findings
- Across 31 included studies and 12,524 participants, the pooled prevalence of ADHD among SUD patients was 21% (95% CI [0.1741; 0.2548]).
- Heterogeneity was very high in the overall model: I² = 95.8%, Q = 721.09, df = 30, p < 0.0001.
- Substance-specific pooled prevalences were 19% for cocaine users (95% CI [0.1058; 0.3102]), 18% for opioid users (95% CI [0.0784; 0.3505]), and 25% for alcohol users (95% CI [0.1845; 0.3360]), each with significant heterogeneity.
- Age had only a slight influence on heterogeneity in the overall model (Q(df = 25) = 20.2909, p = 0.7314), and the funnel plot/Egger test suggested no publication bias (z = −1.69, p = 0.30).
## Methods
- Systematic review and meta-analysis conducted according to PRISMA 2020, searching PUBMED® and Web of Science® from 1970 to 2022 (search conducted 11 May 2022 to 7 July 2022).
- Included peer-reviewed studies with formal DSM or ICD diagnoses of both SUD and ADHD in adults or adolescents; diagnosis based only on self-report questionnaires was excluded.
- Meta-analysis used R/metafor, a random-effects model on logit-transformed proportions, with inverse-variance weighting, DerSimonian-Laird between-study variance, heterogeneity assessed by Q and I², publication bias assessed by funnel plots and Egger intercept, and meta-regression with age as a moderator.
## Limitations
- The paper itself states that the available data were “very heterogeneous,” so the results should be interpreted very cautiously.
- The paper states that it could not conduct moderator analysis for age in the three substance-specific subpopulations because of the small n.
- The paper notes that the substance-specific estimates are based on very few studies and thus should be interpreted with caution; this is evident from the included counts reported for each subgroup.
- The paper also states it excluded 46 studies that relied only on self-reported questionnaires for ADHD diagnosis, which may limit comparability with broader literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 PRISMA 2020 [24] flow diagram.](https://figures.cochat.ai/paper-figures/27240ba4bc264e18b42d78139b7c9755/prevalence-of-attention-deficit-hyperactivity-disorder-adhd-among-substance-use-figure-1.jpg)
![Figure 2 Risk-of-bias traffic light plot [27] of included studies.](https://figures.cochat.ai/paper-figures/67f0b44dc28d495a9d6f5501f0490e1d/prevalence-of-attention-deficit-hyperactivity-disorder-adhd-among-substance-use-figure-2.jpg)
![Figure 3 Risk-of-bias summary plot [27] of included studies.](https://figures.cochat.ai/paper-figures/d561722c59ab435087bacfc1d1e59a34/prevalence-of-attention-deficit-hyperactivity-disorder-adhd-among-substance-use-figure-3.jpg)





Verification
Claims the paper makes
3 Valid · 0 Not valid · 10 Not checked · 20 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Patients with ADHD are more likely to develop SUDs [11] at a younger age [12].”
§ Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) among Substance Use Disorder (SUD) Populations: Meta-Analysis > 1. Introduction
What the sources say
- Supportedcites [11] Lee, 2011, Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: A meta-analytic review, Clin. Psychol. Rev. source
The Discussion (Limitations and Guidelines for Future Research; page not provided) concludes that childhood ADHD is associated with substantially higher risk of several forms of substance abuse or dependence. This supports the risk claim attributed to [11]; the younger-age claim is attributed to [12], not this source. (LLM, conf=0.93)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We estimate the prevalence of ADHD among SUD patients at 21%.”
- Also stated in: § 3.2. Meta-Analytic Findings · plain
“With a random-effects model, we determined the general ADHD prevalence among SUD patients of 21% (95% CI = [0.1741; 0.2548]).”
- Also stated in: § 4. Discussion · hedged
“We estimate the prevalence of ADHD among SUD populations at 21%.”
§ Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) among Substance Use Disorder (SUD) Populations: Meta-Analysis > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 3.2. Meta-Analytic Findings · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For the subpopulation of opioid users, we calculated ADHD prevalence of 18% (95% CI = [0.0784; 0.3505]) with significant heterogeneity (I2= 97.4%, Q = 153.26; df = 4; p < 0.0001).”
- Also stated in: § 4. Discussion · plain
“18% for the opioid SUD population”
§ Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) among Substance Use Disorder (SUD) Populations: Meta-Analysis > 3. Results > 3.2. Meta-Analytic Findings
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 4. Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A moderator analysis was conducted for age, suggesting that age has only a slight influence on heterogeneity, Q (df = 25) = 20.2909, p = 0.7314.”
§ Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) among Substance Use Disorder (SUD) Populations: Meta-Analysis > 3. Results > 3.2. Meta-Analytic Findings
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For the subpopulation of cocaine users, we calculated an ADHD prevalence of 19% (95% CI = [0.1058; 0.3102]) with significant heterogeneity (I2= 96.7%, Q = 238.89; df = 8; p < 0.0001).”
§ Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) among Substance Use Disorder (SUD) Populations: Meta-Analysis > 3. Results > 3.2. Meta-Analytic Findings
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
20 more claims
Create a free account to see all 33 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 3
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Modafinil is generally well tolerated, and the two meta-analyses reported no significant differences in the rate of serious or other adverse events.”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [133]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The evidence is mixed regarding the effectiveness of modafinil in reducing cocaine use in patients with cocaine use disorder.”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [133]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Two meta-analyses found no effect on sustained cocaine abstinence but a positive effect on cocaine abstinence rates at the end of the treatment trial in patients treated with modafinil.132,133”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [133]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Notably, many of the studies included in the meta-analyses reported low medication adherence rates.”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [133]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Modafinil has shown more promising efficacy in certain subpopulations, including those without co-occurring AUD and those with high adherence to treatment.”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [133]
Experimental — accuracy not yet measured
Statistics that don’t add up
Each reported p-value recomputed from its test statistic and degrees of freedom.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“(z = −1.69, p = 0.30”
§ Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) among Substance Use Disorder (SUD) Populations: Meta-Analysis > 3. Results > 3.2. Meta-Analytic Findings
Reported p = .3 · recomputed p = .091
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- Doesn’t add upz = -1.69reported p = .3 · recomputed p = .091
“(z = −1.69, p = .30”
- ConsistentQ(25) = 20.2909reported p = .7314 · recomputed p = .731
“Q (25) = 20.2909, p = .7314”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
McGuinness, L. A., & Higgins, J. P. T. (2021) · Research Synthesis Methods · doi:10.1002/jrsm.1411 · Cited by 5,579 · cited 4×
“Risk-of-bias summary plot [27] of included studies.”
BackgroundMethodInfluentialAssessing heterogeneity in meta-analysis: Q statistic or I² index?
Huedo-Medina, T. B., Sánchez-Meca, J., Marín-Martínez, F., & Botella, J. (2006) · Psychological Methods · doi:10.1037/1082-989x.11.2.193 · Cited by 4,256
Polanczyk, G. V., Willcutt, E. G., Salum, G. A., Kieling, C., & Rohde, L. A. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyt261 · Cited by 1,822 · cited 1×
“Moreover, a meta-regression analysis showed that the geographical location and year of study were not associated with variability in ADHD prevalence estimates [9].”
BackgroundBias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model
Viechtbauer, W. (2005) · Journal of Educational and Behavioral Statistics · doi:10.3102/10769986030003261 · Cited by 1,699 · cited 1×
“Inverse variance weighting was chosen, and between-study variance was calculated using Der Simonian Laird estimator [29].”
MethodPrevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601
Young Adult Outcome of Hyperactive Children: Adaptive Functioning in Major Life Activities
Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000189134.97436.e2 · Cited by 1,027 · cited 1×
“However, around 40–50% of this population continues to experience ADHD symptoms in adolescence and adulthood, while hyperactivity often diminishes and inattention stays more prevalent [7,8].”
BackgroundLee, S. S., Humphreys, K. L., Flory, K., Liu, R., & Glass, K. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2011.01.006 · Cited by 875 · cited 1×
“Patients with ADHD are more likely to develop SUDs [11] at a younger age [12].”
Backgroundvan Emmerik-van Oortmerssen, K., van de Glind, G., van den Brink, W., Smit, F., Crunelle, C. L., Swets, M., & Schoevers, R. A. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.12.007 · Cited by 535
Cited by
The impacts associated with having ADHD: an umbrella review
French, B., Nalbant, G., Wright, H., Sayal, K., Daley, D., Groom, M. J., Cassidy, S., & Hall, C. L. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1343314 · Cited by 144
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Psychiatric comorbidity in substance use disorders, a systematic review of neuro-imaging findings
Tesselaar, D. R. M., Schellekens, A., Homberg, J. R., Booij, J., & Guerrin, C. G. J. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106325 · Cited by 22
Bradlow, R. C. J., Armstrong, F., & Ogden, E. (2025) · The Medical Journal of Australia · doi:10.5694/mja2.70049 · Cited by 13
“15 16-18 Paradoxically, the impairments caused by untreated ADHD — particularly financial instability and poor executive functioning — make it more difficult for affected individuals to navigate the complex and costly process required to obtain a formal diagnosis.”
Genome‐wide association study of delay discounting in Heterogeneous Stock rats
Lara, M. K., Chitre, A. S., Chen, D., Johnson, B. B., Nguyen, K., Cohen, K. A., Muckadam, S. A., Lin, B., Ziegler, S., Beeson, A., et al. (2024) · Genes Brain & Behavior · doi:10.1111/gbb.12909 · Cited by 11
“24,97,98 Functionally, ADGRL3 is involved in synapse development in the cortex 99 and is highly expressed in the brain (proteinatlas. org).”
BackgroundObject Recognition Memory Deficits in ADHD: A Meta-analysis
Lobato-Camacho, F. J., & Faísca, L. (2024) · Neuropsychology Review · doi:10.1007/s11065-024-09645-3 · Cited by 10
Impact of fidget devices on anxiety and physiological responses in adults with ADHD
Elahi, H., Son, H. M., Calub, C. A., Nasiri, N., Shapiro, D. G., Isbister, K., Borden, J., Hastings, P. D., Liu, X., & Schweitzer, J. B. (2025) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2025.104944 · Cited by 7
Three decades of neuroscience research using animal models of ADHD and ASD: a bibliometric analysis
Dougnon, G., & Matsui, H. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1528205 · Cited by 9
Relationship Between Sleep and Immunology in Attention Deficit Hyperactivity Disorder
Jaromirska, J., Sochal, M., Strzelecki, D., Białasiewicz, P., & Gabryelska, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167967 · Cited by 7
“The same study examined the influence of cannabis, showing no significant change depending on ADHD presence [67].”
The Use of Novel Stimulants in ADHD Self-Medication: A Mixed Methods Analysis
Holborn, T., Schifano, F., Smith, E., & Deluca, P. (2025) · Brain Sciences · doi:10.3390/brainsci15030292 · Cited by 8
“%) of substance use disorder (SUD) in adult ADHD [82,83], with the risk of psychiatric comorbidity being increased if the individual has both SUD and ADHD [84].”
ADHD and Alcohol Use Disorder: Optimizing Screening and Treatment in Co-occurring Conditions
Hernández, M., LEVIN, F. R., & Campbell, A. N. C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01168-6 · Cited by 7
“Only a fraction of the 30 million individuals who met diagnostic criteria for an AUD ever receive treatment, and despite an estimated ADHD prevalence of 21% in SUD treatment settings [16, 17], ADHD screening is not standard practice in these programs [6].”
Elefante, C., & Perugi, G. (2025) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000570 · Cited by 4
Baweja, R. K., Waschbusch, D. A., Padilla, F. M., Baweja, R., Singh, B., Pelham, W. E., Molina, B. S. G., Wilens, T. E., & Waxmonsky, J. G. (2025) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2025.12.003 · Cited by 7
Brynte, C., Schellekens, A., Konstenius, M., Begeman, A., Crunelle, C. L., Demetrovics, Z., Dom, G., Icick, R., Johnson, B., Kapitány‐Fövény, M., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112783 · Cited by 6
Gender differences in ADHD and impulsivity among alcohol or alcohol- and cocaine-dependent patients
Roncero, C., Remón-Gallo, D., García-Ullán, L., Vicente-Hernández, B., Buch-Vicente, B., Palma-Álvarez, R. F., Grau‐López, L., González-Bolaños, K. R., Álvarez-Navares, A. I., Pérez, J. M., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1446970 · Cited by 5
Transitioning From Pediatric to Adult Psychiatric Care for ADHD in Sweden: A Nationwide Study
Giacobini, M., Zhao, J., Freilich, J., Malmgren, C., Bernhardsson, N. W., & Ahnemark, E. (2024) · Journal of Attention Disorders · doi:10.1177/10870547241303259 · Cited by 6
Hu, K., Desai, R., Au, S., Zhao, B., Barbic, S. P., Marchand, K., Nicholls, T. L., Schütz, C. G., Samji, H., Hu, J. M., et al. (2025) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2025.101223 · Cited by 8
“9 While estimates range across various mental disorder diagnoses, the World Mental Health Surveys report that nearly 20% of adults with ADHD also have diagnoses of three or more other classes of mental disorders.”
Carbone, M. G., Maremmani, I., Rocca, F. D., Gastaldello, G., Mazzetto, L., Bellini, A., Rizzato, R., Miccichè, R., Tripodi, B., Tagliarini, C., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062222 · Cited by 4
A relação entre o TDAH e Transtorno por Uso de Substâncias em adultos
Rocha, P. A., Rehem, A. J. S. B., Bauer, I. O. B., de Souza, I. B., Oliveira, J. P. A. C. D., & Paiva, L. D. (2024) · LUMEN ET VIRTUS · doi:10.56238/levv15n39-052 · Cited by 13
TDAH et addictions : fardeau ou levier thérapeutique ?
Cabelguen, C., Begnaud, A., & Grall‐Bronnec, M. (2024) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2024.09.004 · Cited by 7
Żełabowski, K., Petrov, W., Ślebioda, D., Rusinek, M., Biedka, K., Błaszczyk, K., Wesołowski, M., Wojtysiak, K., Sroka, M., Ratka, Z., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186470 · Cited by 4
“Rohner et al. [123] have indicated that as many as 21% of individuals grappling with addiction are also diagnosed with ADHD.”
Driving impairment due to psychoactive substances and attention deficit disorder: A pilot study
Terranova, C., Pozzebon, F., Cinquetti, A., Perilli, M., Palumbi, S., Favretto, D., Viel, G., & Aprile, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24083 · Cited by 4
“In their meta-analysis, Rohner et al. incorporated data from 31 studies and determined that the prevalence of ADHD among individuals with SUD was estimated at 21 % [20].”
Ogawa, Y., Tanaka, H., Haga, D., Higashi, Y., Yokota, S., & Tano, K. (2024) · Current Psychology · doi:10.1007/s12144-024-06863-z · Cited by 3
“This can make them more susceptible to developing addiction, including substance abuse (Rohner et al., 2023).”
Greydanus, D. E., Nazeer, A., & Patel, D. R. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2025.101853 · Cited by 4
Baweja, R. K., Pawar, A. K. S., Waxmonsky, J. G., & Wilens, T. E. (2025) · Psychiatric Annals · doi:10.3928/00485713-20250729-01 · Cited by 3
Giulio, P., & Domenico, P. (2023) · Open Journal of Pediatrics and Child Health · doi:10.17352/ojpch.000048 · Cited by 2
Martial arts as complementary interventions to support ADHD-related symptom control
Suchołbiak, A., Mikołajczyk, O., Serafin, A., & Jarzęcka, U. (2025) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2025-0003 · Cited by 3
Karaçul, F. E., & Arslan, G. (2025) · Journal of Attention Disorders · doi:10.1177/10870547251370427 · Cited by 2
“…ADHD symptoms report strained interpersonal relationships (McKee, 2014), more financial instability (Wolfers et al., 2020), greater risk-taking behaviors such as substance use (Rohner et al., 2023), lower self-esteem (Harpin et al., 2013) and over-all lower quality of life (Quintero et al., 2019).”
Horstman, L. I., Koller, D., Cabana‐Domínguez, J., Llonga, N., Icick, R., Vorspan, F., Grau‐López, L., van den Brink, W., Fóthi, Á., Barta, C., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112799 · Cited by 2
Kverno, K. S., & Ramos-Marcuse, F. (2024) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20231212-01 · Cited by 3
Medghalchi, N., Rad, A. H., & Mousavi, M. Z. (2024) · Archives of Neuroscience · doi:10.5812/ans-154348 · Cited by 2
Singh, R. K., Chatterjee, K., & Chauhan, V. S. (2025) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_492_24 · Cited by 2
“[26] Previous studies have noted that the severity of ADHD symptoms was positively correlated with more severe dependence on alcohol.”
Psychopathological investigation of the personality of “psychic mediums”: Clinical evidence
Giulio, P. (2023) · Annals of Psychiatry and Treatment · doi:10.17352/apt.000047 · Cited by 1
Smethells, J. R., Burroughs, D., Saykao, A. T., & LeSage, M. G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1154773 · Cited by 3
Therribout, N., Icick, R., Karsinti, E., Dereux, A., Bellivier, F., Vorspan, F., von Hammerstein, C., & Romo, L. (2024) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2024.08.024 · Cited by 4
Diagnosis and Management of Comorbid ADHD in Patients with Substance Use Disorders
Busch, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-72219-6_50 · Cited by 1
Heck, J., Dubaschewski, M., Krause, O., Bleich, S., Westhoff, M. S., Krichevsky, B., Glahn, A., & Schröder, S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1556920 · Cited by 2
ADHD and schizophrenia: Mere prodromal variant or homogeneous subgroup?
Schulze, J. B., Simnacher, F., Müller, T., Kirchebner, J., Quatela, F., Mikutta, C. A., Euler, S., von Känel, R., & Günther, M. P. (2025) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2025.100374 · Cited by 4
Impulsive suicide in methamphetamine intoxication and self-reported ADHD: a case report
Schallenberg, M., Pietsch, J., Spreer, M., Pilhatsch, M., & Petzold, J. (2025) · Der Nervenarzt · doi:10.1007/s00115-025-01882-y · Cited by 1
Çankaya, P. K. (2025) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.1719949 · Cited by 1
Oliva, H. N. P., Pulido-Saavedra, A., Naveda, A. M. P., Forselius, E., Potenza, M. N., Jegede, O. O., & Angarita, G. A. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1667614 · Cited by 1
Begnaud, A., Cabelguen, C., Challet‐Bouju, G., Leboucher, J., Schreck, B., & Grall‐Bronnec, M. (2025) · Addictive Behaviors · doi:10.1016/j.addbeh.2025.108557 · Cited by 3
Grassi, G., Moradei, C., Cavaliere, S., & Cecchelli, C. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.11.025 · Cited by 3
Long-read whole-genome sequencing of SHR rat substrains with distinct substance use phenotypes
Abdurahaman, A., Lemen, P. M., Kantak, K. M., Baskin, B. M., Bryant, C. D., & Chen, H. (2025) · Mammalian Genome · doi:10.1007/s00335-025-10187-z · Cited by 2
“Given the clinical comorbidity and shared neural mechanisms of ADHD and Substance Use Disorder (SUD) (Rohner et al. 2023), the SHR has also become an important model for studying genetic factors contributing to addiction vulnerability (Sharp et al. 2021; Smethells et al. 2023; Chen et al. 2012;…”
InfluentialCarbone, M. G., Tripodi, B., Matarese, I., Bellini, A., Rizzato, R., Tagliarini, C., Rocca, F. D., Dominicis, F. D., Maremmani, I., Perugi, G., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072688 · Cited by 2
“…and clinical studies consistently demonstrate a bidirectional relationship between ADHD and substance use, whereby ADHD confers an increased risk for the development of SUDs, while substance use may exacerbate attentional deficits, emotional dysregulation, and executive dysfunction [12,13].”
Heriseanu, A. I., Spirou, D., de Moraes, C. E. F., Hay, P., Sichieri, R., & Appolinário, J. C. (2023) · Nutrients · doi:10.3390/nu15132987 · Cited by 1
“Both alcohol and tobacco use are common in attention-deficit/hyperactivity disorder (ADHD); those with ADHD are more likely to develop problematic alcohol and/or tobacco use [18], while ADHD is a common co-morbidity in people with substance use disorders [19].”
BackgroundDas, J., Biswal, J., Mohanty, R., Bose, M., & Parida, S. (2024) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v7i1.756 · Cited by 3
Yusop, M., Mohamed, S., Jaris, N. H., & Jamal, A. (2024) · East Asian Archives of Psychiatry · doi:10.12809/eaap2426 · Cited by 2
Kim, H. H., Silverman, M., Anderson, K. K., Lodhi, R. J., Sarma, S., Dickey, C. C., & Forchuk, C. (2025) · The Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000226 · Cited by 1
“28 Individuals with comorbid stimulant use disorders and ADHD have been reported to have greater substance cravings, as well as greater risk-taking behaviour and impairments in executive functioning.”
Genome-wide association study of delay discounting in Heterogenous Stock ratsPreprint
Lara, M. K., Chitre, A. S., Chen, D., Johnson, B. B., Nguyen, K., Cohen, K. A., Muckadam, S. A., Lin, B., Ziegler, K. S., Beeson, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.12.570851 · Cited by 1
Cultural Perceptions on Attention Deficit Hyperactivity Disorder (過動症) in TaiwanPreprint
Wang, M. (2023) · SocArXiv (OSF Preprints) · doi:10.31235/osf.io/t2nzr
SOCIO-DEMOGRAPHIC CHARACTERISTICS OF INCARCERATED MALE ADULTS WITH ADHD IN SELECTED PRISONS IN KENYA
Waruinge, N., Muaka, C. A., & Tuikong, S. (2023) · European Journal of Social Sciences Studies · doi:10.46827/ejsss.v8i6.1502
Marie, N., & Noble, F. (2024) · Psychotropes · doi:10.3917/psyt.294.0105
Dual Diagnosis: Substance Use Disorders and Co-Occurring Psychiatric Illnesses
Kolla, B. P., Mansukhani, M. P., & Loukianova, L. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00098-1
de Melo, R. C. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2024.tde-19082024-163254 · Cited by 1
Yaseliani, M., Jo, Y., Lindo, L., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5114332
Addictions and Substance Misuse
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg004.pub2
ADHD and problematic substance use
Hjerrild, S., Wissing, S., & Holm, T. (2025) · Ugeskrift for Læger · doi:10.61409/v01250005
A relação entre transtorno por uso de substâncias e TDAH em adultos
Rocha, P. A., Rehem, A. J. S. B., Bauer, I. O. B., de Souza, I. B., de Oliveira, J. P. A. C., & Paiva, L. D. (2025) · Editora Científica Digital eBooks · doi:10.37885/250619465
Han, P. (2025) · Arts Culture and Language · doi:10.61173/wj7zw564
Wu, H., Chou, F. H., Chang, C.-C., Hsu, C.-Y., Chung, K., Lu, Y.-S., Chiu, C.-H., & Li, D. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.08.020
Yaseliani, M., Jo, Y., Lindo, L., Faysal, J. A., & Hasan, M. M. (2025) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2025.209794
ADHS - Komorbiditäten und neue Therapien
Philipsen, A., & Braus, D. F. (2025) · DNP – Die Neurologie & Psychiatrie · doi:10.1007/s15202-025-6536-4
“Auch die hohe ADHS-Prävalenz von mindestens 20 % bei Suchterkrankten einschließlich schwerer Opiatabhängigkeit konnte eindrücklich metaanalytisch belegt werden [6, 7].”
Self-citationCesco, M., Garzitto, M., Pischiutta, L., Lombardelli, T., Moratti, E., Zamparutti, G., Balestrieri, M., Albert, U., & Colizzi, M. (2025) · American Journal on Addictions · doi:10.1111/ajad.70103
“6 ADHD has been found to present with high rates of use of both stimulant and sedative substances, with a prevalence of 19% in people with cocaine ‐ associated SUDs, 18% for opioid ‐ associated, and 25% for alcohol ‐ associated.”
InfluentialJean, F. A. M., Galesne, C., Retuerto, N., Navarro, M. C., Azouz, Z., Tabyaoui, A., Macalli, M., Tzourio, C., & Galéra, C. (2025) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2025.100652
“%) among adults with substance use disorder (Rohner et al., 2023).”
Pallucchini, A., Varese, M., Pergentini, I., Cerrai, E., Gemignani, S., Parapetto, E., Simonetti, F., Maremmani, I., & Maremmani, A. G. I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010089
Zarour, A., Bachmann, C., Dandolo, L., Holstiege, J., Hoffmann, F., Scholman, C., & Golub, Y. (2026) · European Journal of Public Health · doi:10.1093/eurpub/ckaf228
“A recent meta-analysis estimated the prevalence of ADHD among grown-up individuals with SUD at 21%, highlighting ADHD as a common comorbidity associated with an increased risk and earlier onset of severe SUD [29].”
TDAH en milieu judiciaire : des opportunités thérapeutiques ?
Réguidière, C., & Oswald, P. (2026) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2026.02.002
Alhamidi, Z., Lacroix, C., Jouve, É., Soeiro, T., Eiden, C., & Micallef, J. (2026) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70081
“The first is the presence of psychiatric comorbidities among users with cocaine use disorder, which could justify the use of antidepressants and antipsychotics [41, 42].”
Cabelguen, C., Challet‐Bouju, G., Thiabaud, E., Donnio, Y., Lefebvre, L., Hardouin, J.-B., & Grall‐Bronnec, M. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-111698
“22 Substance use, particularly psychostimulants (such as amphetamines and cocaine), sometimes serves as a form of self-medication.”
Adolescence and ADHD: Practical proposals regarding the transition of care
Cabelguen, C., Aoul, S. H., Kammerer, E., Brustolin, D., Shadili, G., Vesproumis, P., Romo, L., & Purper‐Ouakil, D. (2026) · L Encéphale · doi:10.1016/j.encep.2026.01.007 · Cited by 1
Jean, F. A. M. (2023) · theses.fr (ABES) · doi:10.70675/4f836fa7z0a4ez4eb1z9364z9a264cce0262
Therribout, N., Romo, L., Hennequin, T., Chrétienneau, C., Davost, L., Fontaine, T., Bellivier, F., Vorspan, F., Dereux, A., Karsinti, E., et al. (2026) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2026.100682
“…characterized with persistent attention, impulse control and emotional regulation deficits (American Psychiatric Association, 2013) - is found in 23 % of adults suffering from SUD (Rohner et al., 2023; van Emmerik-van Oortmerssen et al., 2012), representing their most frequent chronic comorbidity.”
Perceived stress and addiction severity in adults with ADHD: A multi-domain analysis
Romo, L., Gétin, C., Therribout, N., Icick, R., Fouques, D., & Zerhouni, O. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117189
Shanbhag, T., Rai, S., & Praharaj, S. K. (2026) · Substance Use & Misuse · doi:10.1080/10826084.2026.2670635
Verney, P., Faugère, M., Achour, V., Gavat, J., Maakaron, É., Pailloux, L., Putten, L. V. D., Lançon, C., & Korchia, T. (2026) · L Encéphale · doi:10.1016/j.encep.2026.02.021
Assayag, N., Kirshenboim, Y. B., Nemesh-Godin, T., Zaude, R., Rand, D., & Bar‐Shalita, T. (2026) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s598565
“Given the high prevalence of attention deficit hyperactivity disorder (ADHD) in the SUD population and its potential impact on intervention compliance, 34 this factor was controlled for in the randomization process.”
Demirci, S. C., AŞIK, U. B., Menkü, B. E., Yurtseven, Ç. H., Aksoy, N., Karabulut, A., Tayfur, C., & Arıkan, Z. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08286-5
“A recent meta-analysis based on clinical samples also indicates that the prevalence of ADHD in the general population may be around 21%, highlighting the clinical significance of comorbidity [7].”
Esquivel, L. S., & Vargas, M. R. (2025) · Revista Española de Drogodependencias · doi:10.54108/10136
Shah, M. A., Zaman, S., Khattak, A. Z., & Zaman, M. Z. (2026) · Journal of Substance Use · doi:10.1080/14659891.2026.2698558
Roncero, C., Torres, M. M., Remón-Gallo, D., Aguilar, L., Andrés-Olivera, P., González-Pelaez, P., García-Ullán, L., Cobo-Cuadrado, M. S., & González-Sánchez, A. (2026) · Medical Sciences · doi:10.3390/medsci14030377
Comiskey, C. M., McDonagh, D., Banka, P., James, P. D., Lavelle-Cafferkey, S., & Eustace‐Cook, J. (2026) · Journal of Dual Diagnosis · doi:10.1080/15504263.2026.2686088
“This new estimate within the current meta-analysis is derived from a threefold sample size, confirms the estimate of Rohner et al. (2023), and provides a narrower confidence interval.”
InfluentialADHD medication and the risk for substance use disorder, where do they meet?
Brunt, T. M., Crunelle, C. L., & van den Brink, W. (2026) · Addiction Research & Theory · doi:10.1080/16066359.2026.2699781
Neurodevelopmental reward dysregulation and addiction risk in ADHD
Custodio, R. J. P., Yi, E. C., Kim, B.-N., & Cheong, J. H. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-026-02370-3
Bjørgen, T. G., Reitan, S. K., Lydersen, S., Rasmussen, K. B., & Narud, K. (2026) · Journal of Forensic Psychiatry and Psychology · doi:10.1080/14789949.2026.2726856
“Symptoms of ADHD may continue into adulthood (Faraone et al., 2021; Magon & Müller, 2012; Rohner et al., 2023; Zoccante et al., 2022), and the presence of ADHD complicates the treatment of SUD, often making challenges more severe, chronic, and harder to treat (Barbuti et al., 2023; Ilbegi et al.,…”
Jackson‐Perry, D., Ochoa, S. C., Corbisiero, S., Abela, I. A., Yoon, G. H., Cavassini, M. L., Hampel, B., Amstutz, A., Study, T. S. H. C., & Study, T. S. C. (2026) · medRxiv · doi:10.64898/2026.09.08.26362490
Hasanlı, Z. U., Varlı, M. R., Kurtoğlu, M. B., Katar, K. S., İspir, G. Z., & Danışman, M. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08349-7
“The prevalence of psychiatric conditions such as anxiety disorders [2], depression [3], personality disorders [4], attention-deficit/hyperactivity disorder [5] and bipolar disorder is markedly higher among individuals with SUD compared with the general population [6, 7].”
Gürbüz, A. A., Altun, H., Ekici, F. H., Sarıkaya, H., & Arslan, S. C. (2026) · Journal of Dependence · doi:10.51982/bagimli.626
Setzer, M. R., Kember, R. L., Hartwell, E. E., Piserchia, Z., Gelernter, J. E., Kranzler, H. R., & Gray, J. C. (2026) · Psychological Medicine · doi:10.1017/s0033291725103103
“A recent meta-analysis estimated the prevalence of current ADHD in individuals with SUDs to be 20% (Rohner, Gaspar, Philipsen, & Schulze, 2023).”
Influential
Metadata
- Authors
- Rohner, H., Gaspar, N., Philipsen, A., & Schulze, M.
- Affiliations
- University of Bonn (DE)
- Corresponding author
- Rohner, Henrik
- Gaspar, Nikolas
- ORCID
- Gaspar, Nikolas
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2023-01-10
- Volume
- 20
- Issue
- 2
- Pages
- 1275
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC9859173
- OpenAlex
- W4315498826
- Cited by
- 90
- References
- 58
- Citations by year
- 2026: 25 · 2025: 38 · 2024: 19 · 2023: 8
- FWCI
- 15.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- bonndoc (University of Bonn) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Developmental and Educational Psychology › Children's Physical and Motor Development
- Keywords
- attention deficit hyperactivity disorder, substance use disorders, ADHD prevalence, comorbidities, hyperactivity/impulsivity, inattention
- MeSH terms
- Attention Deficit Disorder with Hyperactivity, Cognition, Humans, Comorbidity, Prevalence, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.